Fentanyl Clinical Guideline Summary

Pharmacology & Mechanism

Potency: Fentanyl is a highly lipid‑soluble synthetic opioid that is 50–100 times more potent than morphine, providing strong mu‑opioid receptor agonism. (National Comprehensive Cancer Network) 1
Cardiovascular profile: Compared with other opioids, fentanyl produces minimal direct cardiovascular effects; any small reductions in blood pressure or heart rate are secondary to vagal stimulation. (American Society of Anesthesiologists) 6
Respiratory safety: The most serious adverse effect is dose‑dependent respiratory depression that can outlast the analgesic effect, occurring across the therapeutic range. (American Society of Anesthesiologists) 3
High‑dose effects: Large intravenous doses may cause chest‑wall rigidity and generalized skeletal‑muscle hypertonicity, making assisted ventilation difficult. (American Society of Anesthesiologists) 4

Chronic cancer pain: Recommended for moderate‑to‑severe chronic cancer pain in opioid‑tolerant patients using the transdermal system. (National Comprehensive Cancer Network) 1
Procedural sedation: Indicated for sedation and analgesia during endoscopic procedures when administered intravenously. (American Society of Anesthesiologists) 3
Breakthrough cancer pain: Transmucosal formulations (lozenge, buccal tablet) are approved for breakthrough pain in opioid‑tolerant cancer patients. (National Comprehensive Cancer Network) 5
Acute ICU pain: Intravenous fentanyl is appropriate for acute pain management in intensive‑care settings. (British Medical Journal) 8
Palliative dyspnea/pain: Used for relief of dyspnea and pain at end of life. (American Thoracic Society) 10

Opioid‑naïve patients: Transdermal fentanyl is contraindicated in patients who are not opioid‑tolerant because of risk of fatal respiratory depression. (National Comprehensive Cancer Network) 1
MAOI use: Concomitant use with monoamine‑oxidase inhibitors can cause life‑threatening reactions (agitation, hemodynamic instability, rigidity, seizures, death). (American Society of Anesthesiologists) 6

Initial dose (opioid‑naïve adults): 50–100 µg IV bolus; supplemental 25 µg every 2–5 min until adequate effect. (American Society of Anesthesiologists) 3
Elderly patients: Reduce total dose by ≥50 %. (American Society of Anesthesiologists) 3
Onset/Duration: Analgesic effect begins in 1–2 min and lasts 30–60 min. (American Society of Anesthesiologists) 3

Starting bolus for opioid‑naïve patients with pain or dyspnea: 2 mg IV, titrated to effect; repeat bolus every 5 min as needed. (Intensive Care Medicine Society) 11
Infusion adjustments: If a patient on infusion develops symptoms, give a bolus equal to twice the hourly infusion rate; double the infusion rate after two boluses within one hour. (Intensive Care Medicine Society) 11

Eligibility: Only for opioid‑tolerant patients; not suitable for rapid titration. (National Comprehensive Cancer Network) 5
Pharmacokinetics: Serum concentrations rise gradually over 12–24 h after patch application due to depot formation in the skin. (National Comprehensive Cancer Network) 2
Conversion: A 1:1 ratio (µg/hr fentanyl patch ≈ µg/hr IV fentanyl) provides a conservative starting point when switching from IV to transdermal. (National Comprehensive Cancer Network) 5

Eligibility: Reserved for opioid‑tolerant patients with breakthrough pain. (National Comprehensive Cancer Network) 5
Starting dose: Begin with the lowest available dose (e.g., 200 µg lozenge or 100 µg buccal tablet) and titrate to effect. (National Comprehensive Cancer Network) 9

Route / Formulation	Conversion to Morphine Equivalent (MME)
Parenteral fentanyl (0.1–0.25 mg IV)	10 mg IV morphine
Chronic dosing: 10 mg IV morphine ≈ 250 µg IV fentanyl (steady state)	—
Transdermal fentanyl (µg/hr)	2.4 MME per µg/hr (MMWR)

Sources: National Comprehensive Cancer Network 1, 2; MMWR Recommendations and Reports 12

Titration principle: Adjust dose to achieve symptom control using the smallest practical increments; no predefined maximum dose. (Intensive Care Medicine Society) 11
Assessment frequency: Pain relief and adverse effects should be evaluated at regular intervals after each dose adjustment. (National Comprehensive Cancer Network) 5
Rescue dosing: Provide short‑acting opioid rescue doses equal to 10–20 % of the 24‑hour total dose every 1–2 h as needed. (National Comprehensive Cancer Network) 9

Respiratory: Continuously monitor respiratory rate, oxygen saturation, and sedation during IV administration; check at least every 4 h for transdermal use. (Intensive Care Medicine Society; British Medical Journal) 11, 8
Hold criteria: Pause infusion or withhold dose if respiratory rate < 8 breaths/min, SpO₂ < 90 %, or PaCO₂ > 55 mm Hg. (Intensive Care Medicine Society) 11
Sedation: Hold for excessive sedation that compromises safety. (Intensive Care Medicine Society; British Medical Journal) 11, 8
Chest‑wall rigidity: Observe for rigidity especially after rapid IV bolus or high doses; be prepared to manage airway. (American Society of Anesthesiologists) 4
Naloxone reversal: After naloxone administration, continue monitoring for at least 2 h because naloxone’s half‑life (30–45 min) is shorter than fentanyl’s. (American Society of Anesthesiologists) 3

Common (>10 %): Nausea/vomiting; constipation (less frequent than oral morphine with transdermal route); sedation/drowsiness. (National Comprehensive Cancer Network) 1
Serious: Respiratory depression (most serious), chest‑wall rigidity with large doses, urinary retention, pruritus. (National Comprehensive Cancer Network) 1

CNS depressants: Benzodiazepines synergistically increase the risk of respiratory depression; when co‑administered, reduce doses of both agents. (American Society of Anesthesiologists) 3
MAOIs: Co‑administration can cause life‑threatening reactions; contraindicated. (American Society of Anesthesiologists) 6

Pain control: Achieve patient‑acceptable pain scores and minimize breakthrough pain episodes. (National Comprehensive Cancer Network) 5
Functional & quality‑of‑life improvement: Enhance functional status and overall quality of life. (National Comprehensive Cancer Network) 1
Safety targets: Maintain respiratory rate > 8 breaths/min and SpO₂ > 90 % while avoiding excessive sedation. (Intensive Care Medicine Society) 11
Gastrointestinal benefit: Transdermal fentanyl results in lower constipation rates compared with oral morphine. (National Comprehensive Cancer Network) 1

Naloxone dosing: 0.2–0.4 mg (0.5–1.0 µg/kg) IV administered every 2–3 min until the desired response is achieved; continue monitoring because naloxone’s half‑life is shorter than fentanyl’s. (American Society of Anesthesiologists) 3